RECRUITING

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

Talk to us

Conditions

Ovarian CancerEpithelial Ovarian CancerPancreatic AdenocarcinomaNeoadjuvant chemotherapy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to see whether participants who are assigned to a multimodal prehabilitation intervention during chemotherapy are able to adhere with exercise and nutrition program to prepare for their cancer surgery.

Official Title

Prehabilitation for Elderly Patients With Advanced Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy

Quick Facts

Study Start:2024-07-23
Study Completion:2025-02-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06412510

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 65 and older
  2. * Patients with diagnosis of advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (EOC) undergoing neoadjuvant chemotherapy; OR Patients with diagnosis of pancreatic adenocarcinoma undergoing neoadjuvant chemotherapy
  1. * Life expectancy less than 3 months in the opinion of the treating physician
  2. * Patients unable to provide informed consent.
  3. * Wheelchair bound patients/ physical immobility.
  4. * Severe cardiopulmonary disease defined as NYHA class III or IV
  5. * Patients with malignant bowel obstruction who will require surgical intervention or nutritional support in the form of enteral or parenteral nutrition will also be excluded.
  6. * Patients with any other comorbidity or condition, which, in the opinion of the enrolling investigator, would place the patient at unnecessarily higher greater risk or burden, or participating in the study would not be in the best interests of the patient.

Contacts and Locations

Study Contact

Mariam AlHilli, MD
CONTACT
216-644-0418
alhillm@ccf.org

Principal Investigator

Mariam AlHilli, MD
PRINCIPAL_INVESTIGATOR
Cleveland Clinic Foundation, Case Comprehensive Cancer Center

Study Locations (Sites)

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195
United States

Collaborators and Investigators

Sponsor: Case Comprehensive Cancer Center

  • Mariam AlHilli, MD, PRINCIPAL_INVESTIGATOR, Cleveland Clinic Foundation, Case Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-23
Study Completion Date2025-02-10

Study Record Updates

Study Start Date2024-07-23
Study Completion Date2025-02-10

Terms related to this study

Keywords Provided by Researchers

  • Ovarian Cancer
  • Neoadjuvant chemotherapy

Additional Relevant MeSH Terms

  • Ovarian Cancer
  • Epithelial Ovarian Cancer
  • Pancreatic Adenocarcinoma